Provider: NIHR Journals Library Content:text/plain; charset="UTF-8" TY - GEN LB - 1. AU - US Food and Drug Administration (FDA), Center for Drug Evaluation and Research TI - Approval Package for Application Number 125514Orig1s014. Trade Name: Keytruda. Generic or Proper Name: Pembrolizumab CY - Rockville, MD PB - FDA PY - 2017 ER - TY - RPRT LB - 2. AU - European Medicines Agency (EMA) TI - Assessment Report: VITRAKVI. International Non-Proprietary Name: Larotrectinib CY - Amsterdam PB - EMA PY - 2019 ER - TY - JOUR LB - 3. AU - Drilon, A AU - Laetsch, TW AU - Kummar, S AU - DuBois, SG AU - Lassen, UN AU - Demetri, GD TI - Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children J2 - N Engl J Med PY - 2018 VL - 378 SP - 731 EP - 739 UR - https://doi.org/10.1056/NEJMoa1714448 ER - TY - GEN LB - 4. AU - National Institute for Health and Care Excellence (NICE) TI - Guide to the Methods of Technology Appraisal CY - London PB - NICE PY - 2013 ER - TY - GEN LB - 5. AU - U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research TI - Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease. Guidance for Industry CY - Silver Spring, MD PB - FDA PY - 2018 ER - TY - GEN LB - 6. AU - U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Oncology Center of Excellence TI - Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics. Guidance for Industry CY - Silver Spring, MD PB - FDA PY - 2018 ER - TY - JOUR LB - 7. AU - Simon, R TI - Optimal two-stage designs for phase II clinical trials J2 - Control Clin Trials PY - 1989 VL - 10 SP - 1 EP - 10 UR - https://doi.org/10.1016/0197-2456(89)90015-9 ER - TY - GEN LB - 8. AU - U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research TI - Guidance for Industry Expedited Programs for Serious Conditions – Drugs and Biologics CY - Silver Spring, MD PB - FDA PY - 2014 ER - TY - GEN LB - 9. AU - U.S. Food and Drug Administration (FDA) TI - Drug Approval Package: Vitrakvi (Larotrectinib) CY - Rockville, MD PB - FDA PY - 2018 UR - www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210861Orig1s000_21171Orig1s000TOC.cfm Y2 - 17 January 2020 ER - TY - GEN LB - 10. AU - U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research TI - Approval Package for Application Number 212725Orig1s000, 212726Orig1s000. Trade Name: ROZLYTREK® Capsules, 100 mg and 200 mg (Entrectinib) CY - Rockville, MD PB - FDA PY - 2019 ER - TY - JOUR LB - 11. AU - Kim, C AU - Prasad, V TI - Strength of validation for surrogate end points used in the US Food and Drug Administration’s approval of oncology drugs J2 - Mayo Clin Proc PY - 2016 VL - 91 SP - 713 EP - 725 UR - https://doi.org/10.1016/j.mayocp.2016.02.012 ER - TY - JOUR LB - 12. AU - Doebele, RC AU - Drilon, A AU - Paz-Ares, L AU - Siena, S AU - Shaw, AT AU - Farago, AF TI - Entrectinib in patients with advanced or metastaticNTRKfusion-positive solid tumours: integrated analysis of three phase 1-2 trials J2 - Lancet Oncol PY - 2020 VL - 21 SP - 271 EP - 282 UR - https://doi.org/10.1016/S1470-2045(19)30691-6 ER - TY - GEN LB - 13. AU - European Medicines Agency (EMA) TI - Workshop on Site and Histology - Independent Indications in Oncology CY - Amsterdam PB - EMA PY - 2017 UR - www.ema.europa.eu/en/events/workshop-site-histology-independent-indications-oncology Y2 - 17 January 2020 ER - TY - GEN LB - 14. AU - European Medicines Agency (EMA) TI - Workshop on Single-arm Trials in Oncology CY - Amsterdam PB - EMA PY - 2016 UR - www.ema.europa.eu/en/events/workshop-single-arm-trials-oncology Y2 - 17 January 2020 ER - TY - GEN LB - 15. AU - European Medicines Agency (EMA) TI - Guideline on the Evaluation of Anticancer Medicinal Products in Man CY - Amsterdam PB - EMA PY - 2017 ER - TY - GEN LB - 16. AU - European Medicines Agency (EMA) TI - Concept Paper on the Revision of the Guideline on the Evaluation of Anticancer Medicinal Products in Man CY - Amsterdam CY - EMA PY - 2018 ER - TY - JOUR LB - 17. AU - Laetsch, TW AU - DuBois, SG AU - Mascarenhas, L AU - Turpin, B AU - Federman, N AU - Albert, CM TI - Larotrectinib for paediatric solid tumours harbouringNTRKfusions: phase 1 results from a multicentre, open-label, phase 1/2 study J2 - Lancet Oncol PY - 2018 VL - 19 SP - 705 EP - 714 UR - https://doi.org/10.1016/S1470-2045(18)30119-0 ER - TY - JOUR LB - 18. AU - Gehan, EA TI - The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent J2 - J Chronic Dis PY - 1961 VL - 13 SP - 346 EP - 353 UR - https://doi.org/10.1016/0021-9681(61)90060-1 ER - TY - JOUR LB - 19. AU - Fleming, TR TI - One-sample multiple testing procedure for phase II clinical trial J2 - Biometrics PY - 1982 VL - 38 SP - 143 EP - 151 UR - https://doi.org/10.2307/2530297 ER - TY - JOUR LB - 20. AU - Lin, Y AU - Shih, WJ TI - Adaptive two-stage designs for single-arm phase IIA cancer clinical trials J2 - Biometrics PY - 2004 VL - 60 SP - 482 EP - 490 UR - https://doi.org/10.1111/j.0006-341X.2004.00193.x ER - TY - JOUR LB - 21. AU - Herson, J TI - Predictive probability early termination plans for phase II clinical trials J2 - Biometrics PY - 1979 VL - 35 SP - 775 EP - 783 UR - https://doi.org/10.2307/2530109 ER - TY - JOUR LB - 22. AU - Thall, PF AU - Simon, R TI - Practical Bayesian guidelines for phase IIB clinical trials J2 - Biometrics PY - 1994 VL - 50 SP - 337 EP - 349 UR - https://doi.org/10.2307/2533377 ER - TY - JOUR LB - 23. AU - Heitjan, DF TI - Bayesian interim analysis of phase II cancer clinical trials J2 - Stat Med PY - 1997 VL - 16 SP - 1791 EP - 1802 UR - https://doi.org/10.1002/(SICI)1097-0258(19970830)16:16<1791::AID-SIM609>3.0.CO;2-E ER - TY - JOUR LB - 24. AU - Tan, SB AU - Machin, D TI - Bayesian two-stage designs for phase II clinical trials J2 - Stat Med PY - 2002 VL - 21 SP - 1991 EP - 2012 UR - https://doi.org/10.1002/sim.1176 ER - TY - JOUR LB - 25. AU - Blagden, SP AU - Billingham, L AU - Brown, LC AU - Buckland, SW AU - Cooper, AM AU - Ellis, S TI - Effective delivery of Complex Innovative Design (CID) cancer trials – a consensus statement J2 - Br J Cancer PY - 2020 VL - 122 SP - 473 EP - 482 UR - https://doi.org/10.1038/s41416-019-0653-9 ER - TY - JOUR LB - 26. AU - Redig, AJ AU - Jänne, PA TI - Basket trials and the evolution of clinical trial design in an era of genomic medicine J2 - J Clin Oncol PY - 2015 VL - 33 SP - 975 EP - 977 UR - https://doi.org/10.1200/JCO.2014.59.8433 ER - TY - JOUR LB - 27. AU - Renfro, LA AU - Sargent, DJ TI - Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples J2 - Ann Oncol PY - 2017 VL - 28 SP - 34 EP - 43 UR - https://doi.org/10.1093/annonc/mdw413 ER - TY - JOUR LB - 28. AU - Hyman, DM AU - Taylor, BS AU - Baselga, J TI - Implementing genome-driven oncology J2 - Cell PY - 2017 VL - 168 SP - 584 EP - 599 UR - https://doi.org/10.1016/j.cell.2016.12.015 ER - TY - JOUR LB - 29. AU - Renfro, LA AU - Mandrekar, SJ TI - Definitions and statistical properties of master protocols for personalized medicine in oncology J2 - J Biopharm Stat PY - 2018 VL - 28 SP - 217 EP - 228 UR - https://doi.org/10.1080/10543406.2017.1372778 ER - TY - JOUR LB - 30. AU - Simon, R TI - New designs for basket clinical trials in oncology J2 - J Biopharm Stat PY - 2018 VL - 28 SP - 245 EP - 255 UR - https://doi.org/10.1080/10543406.2017.1372779 ER - TY - JOUR LB - 31. AU - Lopez-Chavez, A AU - Thomas, A AU - Rajan, A AU - Raffeld, M AU - Morrow, B AU - Kelly, R TI - Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial J2 - J Clin Oncol PY - 2015 VL - 33 SP - 1000 EP - 1007 UR - https://doi.org/10.1200/JCO.2014.58.2007 ER - TY - JOUR LB - 32. AU - Hyman, DM AU - Puzanov, I AU - Subbiah, V AU - Faris, JE AU - Chau, I AU - Blay, JY TI - Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations J2 - N Engl J Med PY - 2015 VL - 373 SP - 726 EP - 736 UR - https://doi.org/10.1056/NEJMoa1502309 ER - TY - JOUR LB - 33. AU - Le Tourneau, C AU - Delord, JP AU - Gonçalves, A AU - Gavoille, C AU - Dubot, C AU - Isambert, N TI - Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial J2 - Lancet Oncol PY - 2015 VL - 16 SP - 1324 EP - 1334 UR - https://doi.org/10.1016/S1470-2045(15)00188-6 ER - TY - JOUR LB - 34. AU - Beckman, RA AU - Antonijevic, Z AU - Kalamegham, R AU - Chen, C TI - Adaptive design for a confirmatory basket trial in multiple tumor types based on a putative predictive biomarker J2 - Clin Pharmacol Ther PY - 2016 VL - 100 SP - 617 EP - 625 UR - https://doi.org/10.1002/cpt.446 ER - TY - BOOK LB - 35. AU - Antonijevic, Z AU - Beckman, R TI - Platform Trial Designs in Drug Development: Umbrella Trials and Basket Trials CY - Boca Raton, FL PB - CRD Press PY - 2019 UR - https://doi.org/10.1201/9781315167756 ER - TY - JOUR LB - 36. AU - Freidlin, B AU - Korn, EL TI - Borrowing information across subgroups in phase II trials: is it useful? J2 - Clin Cancer Res PY - 2013 VL - 19 SP - 1326 EP - 1334 UR - https://doi.org/10.1158/1078-0432.CCR-12-1223 ER - TY - JOUR LB - 37. AU - Simon, R TI - Critical review of umbrella, basket, and platform designs for oncology clinical trials J2 - Clin Pharmacol Ther PY - 2017 VL - 102 SP - 934 EP - 941 UR - https://doi.org/10.1002/cpt.814 ER - TY - CHAP LB - 38. AU - Simon, RM TI - Primary Site Independent Clinical Trials in Oncology A2 - Antonijevic, Z A2 - Beckman, R T2 - Platform Trials in Drug Development: Umbrella Trials and Basket Trials CY - Boca Raton, FL PB - CRC Press PY - 2019 SP - 167 EP - 180 UR - https://doi.org/10.1201/9781315167756-12 ER - TY - JOUR LB - 39. AU - London, WB AU - Chang, MN TI - One- and two-stage designs for stratified phase II clinical trials J2 - Stat Med PY - 2005 VL - 24 SP - 2597 EP - 2611 UR - https://doi.org/10.1002/sim.2139 ER - TY - JOUR LB - 40. AU - Leblanc, M AU - Rankin, C AU - Crowley, J TI - Multiple histology phase II trials J2 - Clin Cancer Res PY - 2009 VL - 15 SP - 4256 EP - 4262 UR - https://doi.org/10.1158/1078-0432.CCR-08-2069 ER - TY - JOUR LB - 41. AU - Jung, SH AU - Chang, MN AU - Kang, SJ TI - Phase II cancer clinical trials with heterogeneous patient populations J2 - J Biopharm Stat PY - 2012 VL - 22 SP - 312 EP - 328 UR - https://doi.org/10.1080/10543406.2010.536873 ER - TY - JOUR LB - 42. AU - Cunanan, KM AU - Iasonos, A AU - Shen, R AU - Begg, CB AU - Gönen, M TI - An efficient basket trial design J2 - Stat Med PY - 2017 VL - 36 SP - 1568 EP - 1579 UR - https://doi.org/10.1002/sim.7227 ER - TY - JOUR LB - 43. AU - Simon, R AU - Geyer, S AU - Subramanian, J AU - Roychowdhury, S TI - The Bayesian basket design for genomic variant-driven phase II trials J2 - Semin Oncol PY - 2016 VL - 43 SP - 13 EP - 18 UR - https://doi.org/10.1053/j.seminoncol.2016.01.002 ER - TY - JOUR LB - 44. AU - Palmer, AC AU - Plana, D AU - Sorger, PK TI - Comparing the efficacy of cancer therapies between subgroups in basket trials J2 - Cell Syst PY - 2020 VL - 11 SP - 449 EP - 60.E2 UR - https://doi.org/10.1101/401620 ER - TY - BOOK LB - 45. AU - Spiegelhalter, DJ AU - Abrams, KR AU - Myles, J TI - Bayesian Approaches to Clinical Trials and Health-Care Evaluation CY - New York, NY PB - Wiley PY - 2004 UR - https://doi.org/10.1002/0470092602 ER - TY - JOUR LB - 46. AU - Thall, PF AU - Wathen, JK AU - Bekele, BN AU - Champlin, RE AU - Baker, LH AU - Benjamin, RS TI - Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes J2 - Stat Med PY - 2003 VL - 22 SP - 763 EP - 780 UR - https://doi.org/10.1002/sim.1399 ER - TY - JOUR LB - 47. AU - Thall, PF AU - Sung, HG TI - Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials J2 - Stat Med PY - 1998 VL - 17 SP - 1563 EP - 1580 UR - https://doi.org/10.1002/(SICI)1097-0258(19980730)17:14%3C1563::AID-SIM873%3E3.0.CO;2-L ER - TY - JOUR LB - 48. AU - Chugh, R AU - Wathen, JK AU - Maki, RG AU - Benjamin, RS AU - Patel, SR AU - Meyers, PA TI - Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model J2 - J Clin Oncol PY - 2009 VL - 27 SP - 3148 EP - 3153 UR - https://doi.org/10.1200/JCO.2008.20.5054 ER - TY - JOUR LB - 49. AU - Berry, SM AU - Broglio, KR AU - Groshen, S AU - Berry, DA TI - Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials J2 - Clin Trials PY - 2013 VL - 10 SP - 720 EP - 734 UR - https://doi.org/10.1177/1740774513497539 ER - TY - JOUR LB - 50. AU - Liu, R AU - Liu, Z AU - Ghadessi, M AU - Vonk, R TI - Increasing the efficiency of oncology basket trials using a Bayesian approach J2 - Contemp Clin Trials PY - 2017 VL - 63 SP - 67 EP - 72 UR - https://doi.org/10.1016/j.cct.2017.06.009 ER - TY - JOUR LB - 51. AU - Neuenschwander, B AU - Wandel, S AU - Roychoudhury, S AU - Bailey, S TI - Robust exchangeability designs for early phase clinical trials with multiple strata J2 - Pharm Stat PY - 2016 VL - 15 SP - 123 EP - 134 UR - https://doi.org/10.1002/pst.1730 ER - TY - JOUR LB - 52. AU - Cunanan, KM AU - Iasonos, A AU - Shen, R AU - Gönen, M TI - Variance prior specification for a basket trial design using Bayesian hierarchical modeling J2 - Clin Trials PY - 2019 VL - 16 SP - 142 EP - 153 UR - https://doi.org/10.1177/1740774518812779 ER - TY - JOUR LB - 53. AU - Leon-Novelo, LG AU - Bekele, BN AU - Müller, P AU - Quintana, F AU - Wathen, K TI - Borrowing strength with nonexchangeable priors over subpopulations J2 - Biometrics PY - 2012 VL - 68 SP - 550 EP - 558 UR - https://doi.org/10.1111/j.1541-0420.2011.01693.x ER - TY - JOUR LB - 54. AU - Chu, Y AU - Yuan, Y TI - BLAST: Bayesian latent subgroup design for basket trials accounting for patient heterogeneity J2 - J R Stat Soc Ser C Appl Stat PY - 2018 VL - 67 SP - 723 EP - 740 UR - https://doi.org/10.1111/rssc.12255 ER - TY - JOUR LB - 55. AU - Chu, Y AU - Yuan, Y TI - A Bayesian basket trial design using a calibrated Bayesian hierarchical model J2 - Clin Trials PY - 2018 VL - 15 SP - 149 EP - 158 UR - https://doi.org/10.1177/1740774518755122 ER - TY - JOUR LB - 56. AU - Fujikawa, K AU - Teramukai, S AU - Yokota, I AU - Daimon, T TI - A Bayesian basket trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability J2 - Biom J PY - 2020 VL - 62 EP - 330 SP - 8 UR - https://doi.org/10.1002/bimj.201800404 ER - TY - JOUR LB - 57. AU - Hobbs, BP AU - Landin, R TI - Bayesian basket trial design with exchangeability monitoring J2 - Stat Med PY - 2018 VL - 37 SP - 3557 EP - 3572 UR - https://doi.org/10.1002/sim.7893 ER - TY - JOUR LB - 58. AU - Flaherty, KT AU - Puzanov, I AU - Kim, KB AU - Ribas, A AU - McArthur, GA AU - Sosman, JA TI - Inhibition of mutated, activated BRAF in metastatic melanoma J2 - N Engl J Med PY - 2010 VL - 363 SP - 809 EP - 819 UR - https://doi.org/10.1056/NEJMoa1002011 ER - TY - JOUR LB - 59. AU - Prahallad, A AU - Sun, C AU - Huang, S AU - Di Nicolantonio, F AU - Salazar, R AU - Zecchin, D TI - Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation ofEGFR J2 - Nature PY - 2012 VL - 483 SP - 100 EP - 103 UR - https://doi.org/10.1038/nature10868 ER - TY - JOUR LB - 60. AU - Heinrich, MC AU - Joensuu, H AU - Demetri, GD AU - Corless, CL AU - Apperley, J AU - Fletcher, JA TI - Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases J2 - Clin Cancer Res PY - 2008 VL - 14 SP - 2717 EP - 2725 UR - https://doi.org/10.1158/1078-0432.CCR-07-4575 ER - TY - JOUR LB - 61. AU - Hudis, CA TI - Trastuzumab – mechanism of action and use in clinical practice J2 - N Engl J Med PY - 2007 VL - 357 SP - 39 EP - 51 UR - https://doi.org/10.1056/NEJMra043186 ER - TY - JOUR LB - 62. AU - Fleming, GF AU - Sill, MW AU - Darcy, KM AU - McMeekin, DS AU - Thigpen, JT AU - Adler, LM TI - Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study J2 - Gynecol Oncol PY - 2010 VL - 116 SP - 15 EP - 20 UR - https://doi.org/10.1016/j.ygyno.2009.09.025 ER - TY - JOUR LB - 63. AU - Gatzemeier, U AU - Groth, G AU - Butts, C AU - van Zandwijk, N AU - Shepherd, F AU - Ardizzoni, A TI - Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer J2 - Ann Oncol PY - 2004 VL - 15 SP - 19 EP - 27 UR - https://doi.org/10.1093/annonc/mdh031 ER - TY - JOUR LB - 64. AU - Cooper, K AU - Tappenden, P AU - Cantrell, A AU - Ennis, K TI - A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer J2 - Br J Cancer PY - 2020 VL - 123 SP - 1686 EP - 1696 UR - https://doi.org/10.1038/s41416-020-01050-w ER - TY - JOUR LB - 65. AU - Fleming, TR AU - Powers, JH TI - Biomarkers and surrogate endpoints in clinical trials J2 - Stat Med PY - 2012 VL - 31 SP - 2973 EP - 2984 UR - https://doi.org/10.1002/sim.5403 ER - TY - JOUR LB - 66. AU - Taylor, RS AU - Elston, J TI - The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports J2 - Health Technol Assess PY - 2009 VL - 13 IS - 8 UR - https://doi.org/10.3310/hta13080 ER - TY - JOUR LB - 67. AU - Fleming, TR AU - DeMets, DL TI - Surrogate end points in clinical trials: are we being misled? J2 - Ann Intern Med PY - 1996 VL - 125 SP - 605 EP - 613 UR - https://doi.org/10.7326/0003-4819-125-7-199610010-00011 ER - TY - JOUR LB - 68. AU - Prentice, RL TI - Surrogate endpoints in clinical trials: definition and operational criteria J2 - Stat Med PY - 1989 VL - 8 SP - 431 EP - 440 UR - https://doi.org/10.1002/sim.4780080407 ER - TY - JOUR LB - 69. AU - Buyse, M AU - Molenberghs, G AU - Burzykowski, T AU - Renard, D AU - Geys, H TI - The validation of surrogate endpoints in meta-analyses of randomized experiments J2 - Biostatistics PY - 2000 VL - 1 SP - 49 EP - 67 UR - https://doi.org/10.1093/biostatistics/1.1.49 ER - TY - JOUR LB - 70. AU - Heller, G TI - Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteria J2 - Ann Oncol PY - 2015 VL - 26 SP - 2012 EP - 2016 UR - https://doi.org/10.1093/annonc/mdv333 ER - TY - JOUR LB - 71. AU - Biomarkers Definitions Working Group TI - Biomarkers and surrogate endpoints: preferred definitions and conceptual framework J2 - Clin Pharmacol Ther PY - 2001 VL - 69 SP - 89 EP - 95 UR - https://doi.org/10.1067/mcp.2001.113989 ER - TY - JOUR LB - 72. AU - Bucher, HC AU - Guyatt, GH AU - Cook, DJ AU - Holbrook, A AU - McAlister, FA TI - Users’ guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points J2 - JAMA PY - 1999 VL - 282 SP - 771 EP - 778 UR - https://doi.org/10.1001/jama.282.8.771 ER - TY - JOUR LB - 73. AU - Elston, J AU - Taylor, RS TI - Use of surrogate outcomes in cost-effectiveness models: a review of United Kingdom health technology assessment reports J2 - Int J Technol Assess Health Care PY - 2009 VL - 25 SP - 6 EP - 13 UR - https://doi.org/10.1017/S0266462309090023 ER - TY - GEN LB - 74. AU - German Institute of Quality and Efficiency in Health Care (IQWiG) TI - Validity of Surrogate Endpoints in Oncology CY - Cologne PB - IQWiG PY - 2011 ER - TY - JOUR LB - 75. AU - Lassere, MN AU - Johnson, KR AU - Schiff, M AU - Rees, D TI - Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES) J2 - BMC Med Res Methodol PY - 2012 VL - 12 SP - 27 UR - https://doi.org/10.1186/1471-2288-12-27 ER - TY - JOUR LB - 76. AU - Buyse, M AU - Molenberghs, G AU - Paoletti, X AU - Oba, K AU - Alonso, A AU - van der Elst, W AU - Burzykowski, T TI - Statistical evaluation of surrogate endpoints with examples from cancer clinical trials J2 - Biom J PY - 2016 VL - 58 SP - 104 EP - 132 UR - https://doi.org/10.1002/bimj.201400049 ER - TY - BOOK LB - 77. AU - Fischer, A AU - Hernandez-Villafuerte, K AU - Latimer, N AU - Henshall, C TI - Extrapolation from Progression-Free Survival to Overall Survival in Oncology CY - London PB - Office of Health Economics PY - 2016 ER - TY - BOOK LB - 78. AU - Davis, S AU - Tappenden, P AU - Cantrell, A TI - A Review of Studies Examining the Relationship Between Progression-free Survival and Overall Survival in Advanced or Metastatic Cancer CY - Sheffield PB - University of Sheffield Report for NICE Decision Support Unit PY - 2012 UR - https://doi.org/10.1016/S0084-3873(12)00197-6 ER - TY - JOUR LB - 79. AU - Savina, M AU - Gourgou, S AU - Italiano, A AU - Dinart, D AU - Rondeau, V AU - Penel, N TI - Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: a critical review J2 - Crit Rev Oncol Hematol PY - 2018 VL - 123 SP - 21 EP - 41 UR - https://doi.org/10.1016/j.critrevonc.2017.11.014 ER - TY - JOUR LB - 80. AU - Haslam, A AU - Hey, SP AU - Gill, J AU - Prasad, V TI - A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology J2 - Eur J Cancer PY - 2019 VL - 106 SP - 196 EP - 211 UR - https://doi.org/10.1016/j.ejca.2018.11.012 ER - TY - JOUR LB - 81. AU - Abdel-Rahman, O TI - Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review J2 - Immunotherapy PY - 2018 VL - 10 SP - 139 EP - 148 UR - https://doi.org/10.2217/imt-2017-0115 ER - TY - JOUR LB - 82. AU - Agarwal, N AU - Bellmunt, J AU - Maughan, BL AU - Boucher, KM AU - Choueiri, TK AU - Qu, AQ TI - Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma J2 - Clin Genitourin Cancer PY - 2014 VL - 12 SP - 130 EP - 137 UR - https://doi.org/10.1016/j.clgc.2013.09.002 ER - TY - JOUR LB - 83. AU - Agarwal, SK AU - Mangal, N AU - Menon, RM AU - Freise, KJ AU - Salem, AH TI - Response rates as predictors of overall survival: a meta-analysis of acute myeloid leukemia trials J2 - J Cancer PY - 2017 VL - 8 SP - 1562 EP - 1567 UR - https://doi.org/10.7150/jca.18686 ER - TY - JOUR LB - 84. AU - Blumenthal, GM AU - Karuri, SW AU - Zhang, H AU - Zhang, L AU - Khozin, S AU - Kazandjian, D TI - Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses J2 - J Clin Oncol PY - 2015 VL - 33 SP - 1008 EP - 1014 UR - https://doi.org/10.1200/JCO.2014.59.0489 ER - TY - JOUR LB - 85. AU - Blumenthal, GM AU - Zhang, L AU - Zhang, H AU - Kazandjian, D AU - Khozin, S AU - Tang, S TI - Milestone analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy in metastatic non-small cell lung cancer trials: a meta-analysis J2 - JAMA Oncol PY - 2017 VL - 3 SP - e171029 UR - https://doi.org/10.1001/jamaoncol.2017.1029 ER - TY - JOUR LB - 86. AU - Bruzzi, P AU - Del Mastro, L AU - Sormani, MP AU - Bastholt, L AU - Danova, M AU - Focan, C TI - Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients J2 - J Clin Oncol PY - 2005 VL - 23 SP - 5117 EP - 5125 UR - https://doi.org/10.1200/JCO.2005.02.106 ER - TY - JOUR LB - 87. AU - Burzykowski, T AU - Buyse, M AU - Piccart-Gebhart, MJ AU - Sledge, G AU - Carmichael, J AU - Lück, HJ TI - Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer J2 - J Clin Oncol PY - 2008 VL - 26 SP - 1987 EP - 1992 UR - https://doi.org/10.1200/JCO.2007.10.8407 ER - TY - JOUR LB - 88. AU - Buyse, M AU - Thirion, P AU - Carlson, RW AU - Burzykowski, T AU - Molenberghs, G AU - Piedbois, P TI - Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer J2 - Lancet PY - 2000 VL - 356 SP - 373 EP - 378 UR - https://doi.org/10.1016/S0140-6736(00)02528-9 ER - TY - JOUR LB - 89. AU - Ciani, O AU - Buyse, M AU - Garside, R AU - Peters, J AU - Saad, ED AU - Stein, K AU - Taylor, RS TI - Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer J2 - J Clin Epidemiol PY - 2015 VL - 68 SP - 833 EP - 842 UR - https://doi.org/10.1016/j.jclinepi.2015.02.016 ER - TY - JOUR LB - 90. AU - Colloca, G AU - Venturino, A TI - Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer J2 - Med Oncol PY - 2017 VL - 34 SP - 87 UR - https://doi.org/10.1007/s12032-017-0939-9 ER - TY - JOUR LB - 91. AU - Colloca, G AU - Venturino, A AU - Guarneri, D TI - Analysis of response-related and time-to-event endpoints in randomized trials of gemcitabine-based treatment versus gemcitabine alone as first-line treatment of patients with advanced pancreatic cancer J2 - Clin Colorectal Cancer PY - 2016 VL - 15 SP - 264 EP - 276 UR - https://doi.org/10.1016/j.clcc.2015.11.006 ER - TY - JOUR LB - 92. AU - Colloca, G AU - Venturino, A AU - Guarneri, D TI - Analysis of clinical end points of randomised trials including bevacizumab and chemotherapy versus chemotherapy as first-line treatment of metastatic colorectal cancer J2 - Clin Oncol PY - 2016 VL - 28 SP - e155 EP - e164 UR - https://doi.org/10.1016/j.clon.2016.05.001 ER - TY - JOUR LB - 93. AU - Colloca, G AU - Vitucci, P AU - Venturino, A TI - Trial level analysis of prostate-specific antigen-related versus unrelated endpoints in phase III trials of first-line and second-line medical treatments of patients with metastatic castration-resistant prostate cancer J2 - Clin Genitourin Cancer PY - 2016 VL - 14 SP - 389 EP - 397 UR - https://doi.org/10.1016/j.clgc.2016.03.022 ER - TY - JOUR LB - 94. AU - Cremolini, C AU - Antoniotti, C AU - Pietrantonio, F AU - Berenato, R AU - Tampellini, M AU - Baratelli, C TI - Surrogate endpoints in second-line trials of targeted agents in metastatic colorectal cancer: a literature-based systematic review and meta-analysis J2 - Cancer Res Treat PY - 2017 VL - 49 SP - 834 EP - 845 UR - https://doi.org/10.4143/crt.2016.249 ER - TY - JOUR LB - 95. AU - Delea, TE AU - Khuu, A AU - Heng, DY AU - Haas, T AU - Soulières, D TI - Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma J2 - Br J Cancer PY - 2012 VL - 107 SP - 1059 EP - 1068 UR - https://doi.org/10.1038/bjc.2012.367 ER - TY - JOUR LB - 96. AU - Elia, EG AU - Städler, N AU - Ciani, O AU - Taylor, RS AU - Bujkiewicz, S TI - Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer J2 - Cancer Epidemiol PY - 2020 VL - 64 SP - 101665 UR - https://doi.org/10.1016/j.canep.2019.101665 ER - TY - JOUR LB - 97. AU - Foster, NR AU - Qi, Y AU - Shi, Q AU - Krook, JE AU - Kugler, JW AU - Jett, JR TI - Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials J2 - Cancer PY - 2011 VL - 117 SP - 1262 EP - 1271 UR - https://doi.org/10.1002/cncr.25526 ER - TY - JOUR LB - 98. AU - Giessen, C AU - Laubender, RP AU - Ankerst, DP AU - Stintzing, S AU - Modest, DP AU - Schulz, C TI - Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials J2 - Acta Oncol PY - 2015 VL - 54 SP - 187 EP - 193 UR - https://doi.org/10.3109/0284186X.2014.938830 ER - TY - JOUR LB - 99. AU - Hackshaw, A AU - Knight, A AU - Barrett-Lee, P AU - Leonard, R TI - Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer J2 - Br J Cancer PY - 2005 VL - 93 SP - 1215 EP - 1221 UR - https://doi.org/10.1038/sj.bjc.6602858 ER - TY - JOUR LB - 100. AU - Hamada, T AU - Nakai, Y AU - Isayama, H AU - Yasunaga, H AU - Matsui, H AU - Takahara, N TI - Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer J2 - Eur J Cancer PY - 2016 VL - 65 SP - 11 EP - 20 UR - https://doi.org/10.1016/j.ejca.2016.05.016 ER - TY - JOUR LB - 101. AU - Han, K AU - Ren, M AU - Wick, W AU - Abrey, L AU - Das, A AU - Jin, J AU - Reardon, DA TI - Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials J2 - Neuro Oncol PY - 2014 VL - 16 SP - 696 EP - 706 UR - https://doi.org/10.1093/neuonc/not236 ER - TY - JOUR LB - 102. AU - Hashim, M AU - Pfeiffer, BM AU - Bartsch, R AU - Postma, M AU - Heeg, B TI - Do surrogate endpoints better correlate with overall survival in studies that did not allow for crossover or reported balanced postprogression treatments? An application in advanced non-small cell lung cancer J2 - Value Health PY - 2018 VL - 21 SP - 9 EP - 17 UR - https://doi.org/10.1016/j.jval.2017.07.011 ER - TY - JOUR LB - 103. AU - Hotta, K AU - Kato, Y AU - Leighl, N AU - Takigawa, N AU - Gaafar, RM AU - Kayatani, H TI - Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review J2 - PLOS ONE PY - 2015 VL - 10 SP - e0121211 UR - https://doi.org/10.1371/journal.pone.0121211 ER - TY - JOUR LB - 104. AU - Hotta, K AU - Kiura, K AU - Fujiwara, Y AU - Takigawa, N AU - Oze, I AU - Ochi, N TI - Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer J2 - Ann Oncol PY - 2009 VL - 20 SP - 829 EP - 834 UR - https://doi.org/10.1093/annonc/mdp020 ER - TY - JOUR LB - 105. AU - Ichikawa, W AU - Sasaki, Y TI - Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients J2 - Ann Oncol PY - 2006 VL - 17 SP - 1665 EP - 1672 UR - https://doi.org/10.1093/annonc/mdl174 ER - TY - JOUR LB - 106. AU - Imaoka, H AU - Sasaki, M AU - Takahashi, H AU - Hashimoto, Y AU - Ohno, I AU - Mitsunaga, S TI - Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms J2 - Endocr Relat Cancer PY - 2017 VL - 24 SP - 475 EP - 483 UR - https://doi.org/10.1530/ERC-17-0197 ER - TY - JOUR LB - 107. AU - Imaoka, H AU - Sasaki, M AU - Takahashi, H AU - Hashimoto, Y AU - Ohno, I AU - Mitsunaga, S TI - Alternate endpoints for phase II trials in advanced neuroendocrine tumors J2 - Oncologist PY - 2019 VL - 24 SP - 47 EP - 53 UR - https://doi.org/10.1634/theoncologist.2017-0651 ER - TY - JOUR LB - 108. AU - Iezzi, R AU - Pompili, M AU - Rinninella, E AU - Annicchiarico, E AU - Garcovich, M AU - Cerrito, L TI - TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib J2 - Eur Radiol PY - 2019 VL - 29 SP - 1285 EP - 1292 UR - https://doi.org/10.1007/s00330-018-5692-8 ER - TY - JOUR LB - 109. AU - Johnson, KR AU - Ringland, C AU - Stokes, BJ AU - Anthony, DM AU - Freemantle, N AU - Irs, A TI - Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis J2 - Lancet Oncol PY - 2006 VL - 7 SP - 741 EP - 746 UR - https://doi.org/10.1016/S1470-2045(06)70800-2 ER - TY - JOUR LB - 110. AU - Kaufman, HL AU - Schwartz, LH AU - William, WN AU - Sznol, M AU - Fahrbach, K AU - Xu, Y TI - Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis J2 - J Cancer Res Clin Oncol PY - 2018 VL - 144 SP - 2245 EP - 2261 UR - https://doi.org/10.1007/s00432-018-2738-x ER - TY - JOUR LB - 111. AU - Lee, L AU - Wang, L AU - Crump, M TI - Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin’s lymphoma: correlation of complete response, time-to-event and overall survival end points J2 - Ann Oncol PY - 2011 VL - 22 SP - 1392 EP - 1403 UR - https://doi.org/10.1093/annonc/mdq615 ER - TY - JOUR LB - 112. AU - Li, J AU - He, Q AU - Yu, X AU - Khan, K AU - Weng, X AU - Guan, M TI - Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials J2 - Cancer Manag Res PY - 2019 VL - 11 SP - 1623 EP - 1629 UR - https://doi.org/10.2147/CMAR.S188551 ER - TY - JOUR LB - 113. AU - Li, X AU - Liu, S AU - Gu, H AU - Wang, D TI - Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib J2 - J Cancer Res Clin Oncol PY - 2012 VL - 138 SP - 1963 EP - 1969 UR - https://doi.org/10.1007/s00432-012-1278-z ER - TY - JOUR LB - 114. AU - Liu, L AU - Chen, F AU - Zhao, J AU - Yu, H TI - Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: literature-based analysis of 24 randomized trials J2 - Bull Cancer PY - 2016 VL - 103 SP - 336 EP - 344 UR - https://doi.org/10.1016/j.bulcan.2016.01.002 ER - TY - JOUR LB - 115. AU - Louvet, C AU - de Gramont, A AU - Tournigand, C AU - Artru, P AU - Maindrault-Goebel, F AU - Krulik, M TI - Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma J2 - Cancer PY - 2001 VL - 91 SP - 2033 EP - 2038 UR - https://doi.org/10.1002/1097-0142(20010601)91:11<2033::AID-CNCR1229>3.0.CO;2-J ER - TY - JOUR LB - 116. AU - Makris, EA AU - MacBarb, R AU - Harvey, DJ AU - Poultsides, GA TI - Surrogate end points for overall survival in metastatic, locally advanced, or unresectable pancreatic cancer: a systematic review and meta-analysis of 24 randomized controlled trials J2 - Ann Surg Oncol PY - 2017 VL - 24 SP - 2371 EP - 2378 UR - https://doi.org/10.1245/s10434-017-5826-2 ER - TY - JOUR LB - 117. AU - Mangal, N AU - Salem, AH AU - Li, M AU - Menon, R AU - Freise, KJ TI - Relationship between response rates and median progression-free survival in non-Hodgkin’s lymphoma: a meta-analysis of published clinical trials J2 - Hematol Oncol PY - 2018 VL - 36 SP - 37 EP - 43 UR - https://doi.org/10.1002/hon.2463 ER - TY - JOUR LB - 118. AU - Mangal, N AU - Salem, AH AU - Menon, RM AU - Freise, KJ TI - Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: evaluation of results from 102 clinical trials J2 - Hematol Oncol PY - 2018 VL - 36 SP - 547 EP - 553 UR - https://doi.org/10.1002/hon.2514 ER - TY - JOUR LB - 119. AU - Moriwaki, T AU - Yamamoto, Y AU - Gosho, M AU - Kobayashi, M AU - Sugaya, A AU - Yamada, T TI - Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy J2 - Br J Cancer PY - 2016 VL - 114 SP - 881 EP - 888 UR - https://doi.org/10.1038/bjc.2016.83 ER - TY - JOUR LB - 120. AU - Mushti, SL AU - Mulkey, F AU - Sridhara, R TI - Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials J2 - Clin Cancer Res PY - 2018 VL - 24 SP - 2268 EP - 2275 UR - https://doi.org/10.1158/1078-0432.CCR-17-1902 ER - TY - JOUR LB - 121. AU - Nakashima, K AU - Horita, N AU - Nagai, K AU - Manabe, S AU - Murakami, S AU - Ota, E AU - Kaneko, T TI - Progression-free survival, response rate, and disease control rate as predictors of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for advanced, locally advanced, and recurrent non-small cell lung carcinoma J2 - J Thorac Oncol PY - 2016 VL - 11 SP - 1574 EP - 1585 UR - https://doi.org/10.1016/j.jtho.2016.04.025 ER - TY - JOUR LB - 122. AU - Nickolich, M AU - Babakoohi, S AU - Fu, P AU - Dowlati, A TI - Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution J2 - Clin Lung Cancer PY - 2014 VL - 15 SP - 207 EP - 212 UR - https://doi.org/10.1016/j.cllc.2013.12.001 ER - TY - JOUR LB - 123. AU - Nie, RC AU - Chen, FP AU - Yuan, SQ AU - Luo, YS AU - Chen, S AU - Chen, YM TI - Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials J2 - Eur J Cancer PY - 2019 VL - 106 SP - 1 EP - 11 UR - https://doi.org/10.1016/j.ejca.2018.10.011 ER - TY - JOUR LB - 124. AU - Pang, Y AU - Shen, Z AU - Sun, J AU - Wang, W TI - Does the use of targeted agents in advanced gastroesophageal cancer increase complete response? A meta-analysis of 18 randomized controlled trials J2 - Cancer Manag Res PY - 2018 VL - 10 SP - 5505 EP - 5514 UR - https://doi.org/10.2147/CMAR.S174063 ER - TY - JOUR LB - 125. AU - Penel, N AU - Ryckewaert, T AU - Kramar, A TI - What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials J2 - Bull Cancer PY - 2014 VL - 101 SP - E19 EP - E24 UR - https://doi.org/10.1684/bdc.2014.1934 ER - TY - JOUR LB - 126. AU - Petrelli, F AU - Barni, S TI - Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapies J2 - Clin Genitourin Cancer PY - 2013 VL - 11 SP - 385 EP - 389 UR - https://doi.org/10.1016/j.clgc.2013.07.012 ER - TY - JOUR LB - 127. AU - Petrelli, F AU - Barni, S TI - Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials J2 - Med Oncol PY - 2014 VL - 31 SP - 776 UR - https://doi.org/10.1007/s12032-013-0776-4 ER - TY - JOUR LB - 128. AU - Ritchie, G AU - Gasper, H AU - Man, J AU - Lord, S AU - Marschner, I AU - Friedlander, M AU - Lee, CK TI - Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis J2 - JAMA Oncol PY - 2018 VL - 4 SP - 522 EP - 528 UR - https://doi.org/10.1001/jamaoncol.2017.5236 ER - TY - JOUR LB - 129. AU - Rose, PG AU - Tian, C AU - Bookman, MA TI - Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study J2 - Gynecol Oncol PY - 2010 VL - 117 SP - 324 EP - 329 UR - https://doi.org/10.1016/j.ygyno.2010.01.040 ER - TY - JOUR LB - 130. AU - Roviello, G AU - Andre, F AU - Venturini, S AU - Pistilli, B AU - Curigliano, G AU - Cristofanilli, M TI - Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: a meta-regression of randomised prospective studies J2 - Eur J Cancer PY - 2017 VL - 86 SP - 257 EP - 265 UR - https://doi.org/10.1016/j.ejca.2017.09.018 ER - TY - JOUR LB - 131. AU - Sekine, I AU - Tamura, T AU - Kunitoh, H AU - Kubota, K AU - Shinkai, T AU - Kamiya, Y AU - Saijo, N TI - Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer J2 - Ann Oncol PY - 1999 VL - 10 SP - 731 EP - 733 UR - https://doi.org/10.1023/a:1008303921033 ER - TY - JOUR LB - 132. AU - Shi, Q AU - Flowers, CR AU - Hiddemann, W AU - Marcus, R AU - Herold, M AU - Hagenbeek, A TI - Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials J2 - J Clin Oncol PY - 2017 VL - 35 SP - 552 EP - 560 UR - https://doi.org/10.1200/JCO.2016.70.8651 ER - TY - JOUR LB - 133. AU - Shitara, K AU - Matsuo, K AU - Muro, K AU - Doi, T AU - Ohtsu, A TI - Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer J2 - Gastric Cancer PY - 2014 VL - 17 SP - 362 EP - 370 UR - https://doi.org/10.1007/s10120-013-0274-6 ER - TY - JOUR LB - 134. AU - Shukuya, T AU - Mori, K AU - Amann, JM AU - Bertino, EM AU - Otterson, GA AU - Shields, PG TI - Relationship between overall survival and response or progression-free survival in advanced non-small cell lung cancer patients treated with anti-PD-1/PD-L1 antibodies J2 - J Thorac Oncol PY - 2016 VL - 11 SP - 1927 EP - 1939 UR - https://doi.org/10.1016/j.jtho.2016.07.017 ER - TY - JOUR LB - 135. AU - Siddiqui, MK AU - Tyczynski, J AU - Pahwa, A AU - Fernandes, AW TI - Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer J2 - Gynecol Oncol PY - 2017 VL - 146 SP - 44 EP - 51 UR - https://doi.org/10.1016/j.ygyno.2017.03.515 ER - TY - JOUR LB - 136. AU - Sidhu, R AU - Rong, A AU - Dahlberg, S TI - Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials J2 - Clin Cancer Res PY - 2013 VL - 19 SP - 969 EP - 976 UR - https://doi.org/10.1158/1078-0432.CCR-12-2502 ER - TY - JOUR LB - 137. AU - Tanaka, K AU - Kawano, M AU - Iwasaki, T AU - Itonaga, I AU - Tsumura, H TI - Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation J2 - BMC Cancer PY - 2019 VL - 19 SP - 56 UR - https://doi.org/10.1186/s12885-019-5268-2 ER - TY - JOUR LB - 138. AU - Tang, PA AU - Bentzen, SM AU - Chen, EX AU - Siu, LL TI - Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy J2 - J Clin Oncol PY - 2007 VL - 25 SP - 4562 EP - 4568 UR - https://doi.org/10.1200/JCO.2006.08.1935 ER - TY - JOUR LB - 139. AU - Tsujino, K AU - Kawaguchi, T AU - Kubo, A AU - Aono, N AU - Nakao, K AU - Koh, Y TI - Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib J2 - J Thorac Oncol PY - 2009 VL - 4 SP - 994 EP - 1001 UR - https://doi.org/10.1097/JTO.0b013e3181a94a2f ER - TY - JOUR LB - 140. AU - Tsujino, K AU - Shiraishi, J AU - Tsuji, T AU - Kurata, T AU - Kawaguchi, T AU - Kubo, A TI - Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer? J2 - Ann Oncol PY - 2010 VL - 21 SP - 1668 EP - 1674 ER - TY - JOUR LB - 141. AU - Vidaurre, T AU - Wilkerson, J AU - Simon, R AU - Bates, SE AU - Fojo, T TI - Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development J2 - Cancer J PY - 2009 VL - 15 SP - 366 EP - 373 UR - https://doi.org/10.1097/PPO.0b013e3181b9d37b ER - TY - JOUR LB - 142. AU - Wilkerson, J AU - Fojo, T TI - Progression-free survival is simply a measure of a drug’s effect while administered and is not a surrogate for overall survival J2 - Cancer J PY - 2009 VL - 15 SP - 379 EP - 385 UR - https://doi.org/10.1097/PPO.0b013e3181bef8cd ER - TY - JOUR LB - 143. AU - Zer, A AU - Prince, RM AU - Amir, E AU - Abdul Razak, A TI - Evolution of randomized trials in advanced/metastatic soft tissue sarcoma: end point selection, surrogacy, and quality of reporting J2 - J Clin Oncol PY - 2016 VL - 34 SP - 1469 EP - 1475 UR - https://doi.org/10.1200/JCO.2015.64.3437 ER - TY - JOUR LB - 144. AU - Zhu, R AU - Lu, D AU - Chu, YW AU - Chai, A AU - Green, M AU - Zhang, N AU - Jin, JY TI - Assessment of correlation between early and late efficacy endpoints to identify potential surrogacy relationships in non-Hodgkin lymphoma: a literature-based meta-analysis of 108 phase II and phase III studies J2 - AAPS J PY - 2017 VL - 19 SP - 669 EP - 681 UR - https://doi.org/10.1208/s12248-017-0056-x ER - TY - JOUR LB - 145. AU - Ito, K AU - Miura, S AU - Sakaguchi, T AU - Murotani, K AU - Horita, N AU - Akamatsu, H TI - The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer J2 - Lung Cancer PY - 2019 VL - 128 SP - 113 EP - 119 UR - https://doi.org/10.1016/j.lungcan.2018.12.023 ER - TY - RPRT LB - 146. AU - Bujkiewicz, S AU - Achana, F AU - Papanikos, T AU - Riley, RD AU - Abrams, KR TI - NICE DSU Technical Support Document 20: Multivariate Meta-analysis of Summary Data for Combining Treatment Effects on Correlated Outcomes and Evaluating Surrogate Endpoints. Report by The Decision Support Unit CY - Sheffield PB - Decision Support Unit, ScHARR, University of Sheffield PY - 2019 ER - TY - JOUR LB - 147. AU - Bujkiewicz, S AU - Jackson, D AU - Thompson, JR AU - Turner, RM AU - Städler, N AU - Abrams, KR AU - White, IR TI - Bivariate network meta-analysis for surrogate endpoint evaluation J2 - Stat Med PY - 2019 VL - 38 SP - 3322 EP - 3341 UR - https://doi.org/10.1002/sim.8187 ER - TY - JOUR LB - 148. AU - Murphy, P AU - Claxton, L AU - Hodgson, R AU - Glynn, D AU - Beresford, L AU - Walton, M TI - Exploring heterogeneity in histology-independent technologies and the implications for cost-effectiveness J2 - Med Decis Making PY - 2021 VL - 41 SP - 165 EP - 178 UR - https://doi.org/10.1177/0272989X20980327 ER - TY - JOUR LB - 149. AU - Phelps, CE AU - Mushlin, AI TI - Focusing technology assessment using medical decision theory J2 - Med Decis Making PY - 1988 VL - 8 SP - 279 EP - 289 UR - https://doi.org/10.1177/0272989X8800800409 ER - TY - JOUR LB - 150. AU - Coyle, D AU - Buxton, MJ AU - O’Brien, BJ TI - Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria J2 - Health Econ PY - 2003 VL - 12 SP - 421 EP - 427 UR - https://doi.org/10.1002/hec.788 ER - TY - JOUR LB - 151. AU - Espinoza, MA AU - Manca, A AU - Claxton, K AU - Sculpher, MJ TI - The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application J2 - Med Decis Making PY - 2014 VL - 34 SP - 951 EP - 964 UR - https://doi.org/10.1177/0272989X14538705 ER - TY - JOUR LB - 152. AU - Basu, A AU - Meltzer, D TI - Value of information on preference heterogeneity and individualized care J2 - Med Decis Making PY - 2007 VL - 27 SP - 112 EP - 127 UR - https://doi.org/10.1177/0272989X06297393 ER - TY - BOOK LB - 153. AU - Cancer Research, UK TI - Cancer Research UK Policy Statement: Patient Access to Molecular Diagnostics and Targeted Medicines in England CY - London PB - Cancer Research UK PY - 2018 ER - TY - BOOK LB - 154. AU - Lunn, D AU - Jackson, C AU - Best, N AU - Thomas, A AU - Spiegelhalter, D TI - The BUGS Book CY - Boca Raton, FL PB - CRC Press PY - 2013 UR - https://doi.org/10.1201/b13613 ER - TY - JOUR LB - 155. AU - Sturtz, S AU - Ligges, U AU - Gelman, A TI - R2WinBUGS: a package for running WinBUGS from R J2 - J Stat Softw PY - 2005 VL - 12 SP - 1 EP - 16 UR - www.jstatsoft.org/v2/i03 ER - TY - JOUR LB - 156. AU - Brooks, SP AU - Gelman, A TI - General methods for monitoring convergence of iterative simulations J2 - J Comput Graph Stat PY - 1998 VL - 7 SP - 434 EP - 455 UR - https://doi.org/10.1080/10618600.1998.10474787 ER - TY - JOUR LB - 157. AU - Gelman, A AU - Rubin, DB TI - Inferences from iterative simulation using multiple sequences J2 - Stat Sci PY - 1992 VL - 7 SP - 457 EP - 472 UR - https://doi.org/10.1214/ss/1177011136 ER - TY - GEN LB - 158. AU - National Institute for Health and Care Excellence (NICE) TI - Larotrectinib for TreatingNTRKFusion-positive Advanced Solid Tumours IS - Technology Appraisal Guidance [TA630] CY - London PB - NICE PY - 2019 ER - TY - JOUR LB - 159. AU - Bongarzone, I AU - Vigneri, P AU - Mariani, L AU - Collini, P AU - Pilotti, S AU - Pierotti, MA TI - RET/NTRK1rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features J2 - Clin Cancer Res PY - 1998 VL - 4 SP - 223 EP - 228 ER - TY - JOUR LB - 160. AU - Prasad, ML AU - Vyas, M AU - Horne, MJ AU - Virk, RK AU - Morotti, R AU - Liu, Z TI - NTRKfusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States J2 - Cancer PY - 2016 VL - 122 SP - 1097 EP - 1107 UR - https://doi.org/10.1002/cncr.29887 ER - TY - JOUR LB - 161. AU - Vokuhl, C AU - Nourkami-Tutdibi, N AU - Furtwängler, R AU - Gessler, M AU - Graf, N AU - Leuschner, I TI - ETV6–NTRK3in congenital mesoblastic nephroma: a report of the SIOP/GPOH nephroblastoma study J2 - Pediatr Blood Cancer PY - 2018 VL - 65 EP - e26925 UR - https://doi.org/10.1002/pbc.26925 ER - TY - BOOK LB - 162. AU - Phillippo, DM AU - Ades, AE AU - Dias, S AU - Palmer, S AU - Abrams, KR AU - Welton, NJ TI - NICE DSU Technical Support Document 18: Methods for Population-adjusted Indirect Comparisons in Submissions to NICE CY - Sheffield PB - ScHARR, University of Sheffield PY - 2016 ER - TY - JOUR LB - 163. AU - Hatswell, AJ AU - Thompson, GJ AU - Maroudas, PA AU - Sofrygin, O AU - Delea, TE TI - Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia J2 - Cost Eff Resour Alloc PY - 2017 VL - 15 SP - 8 UR - https://doi.org/10.1186/s12962-017-0071-x ER - TY - JOUR LB - 164. AU - Hatswell, AJ AU - Sullivan, WG TI - Creating historical controls using data from a previous line of treatment – two non-standard approaches J2 - Stat Methods Med Res PY - 2020 VL - 29 SP - 1563 EP - 1572 UR - https://doi.org/10.1177/0962280219826609 ER - TY - JOUR LB - 165. AU - Hsiao, SJ AU - Zehir, A AU - Sireci, AN AU - Aisner, DL TI - Detection of tumorNTRKgene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy J2 - J Mol Diagn PY - 2019 VL - 21 SP - 553 EP - 571 UR - https://doi.org/10.1016/j.jmoldx.2019.03.008 ER - TY - ELEC LB - 166. AU - NHS England TI - National Genomic Test Directory PY - 2019 UR - www.england.nhs.uk/publication/national-genomic-test-directories/ M1 - 15 May 2019 ER - TY - JOUR LB - 167. AU - Vogelstein, B AU - Kinzler, KW TI - Cancer genes and the pathways they control J2 - Nat Med PY - 2004 VL - 10 SP - 789 EP - 799 UR - https://doi.org/10.1038/nm1087 ER - TY - JOUR LB - 168. AU - Morganti, S AU - Tarantino, P AU - Ferraro, E AU - D’Amico, P AU - Viale, G AU - Trapani, D TI - Complexity of genome sequencing and reporting: next generation sequencing (NGS) technologies and implementation of precision medicine in real life J2 - Crit Rev Oncol Hematol PY - 2019 VL - 133 SP - 171 EP - 182 UR - https://doi.org/10.1016/j.critrevonc.2018.11.008 ER - TY - JOUR LB - 169. AU - Eifert, C AU - Powers, RS TI - From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets J2 - Nat Rev Cancer PY - 2012 VL - 12 SP - 572 EP - 578 UR - https://doi.org/10.1038/nrc3299 ER - TY - JOUR LB - 170. AU - Sheikine, Y AU - Kuo, FC AU - Lindeman, NI TI - Clinical and technical aspects of genomic diagnostics for precision oncology J2 - J Clin Oncol PY - 2017 VL - 35 SP - 929 EP - 933 UR - https://doi.org/10.1200/JCO.2016.70.7539 ER - TY - JOUR LB - 171. AU - Solomon, JP AU - Hechtman, JF TI - Detection ofNTRKfusions: merits and limitations of current diagnostic platforms J2 - Cancer Res PY - 2019 VL - 79 SP - 3163 EP - 3168 UR - https://doi.org/10.1158/0008-5472.CAN-19-0372 ER - TY - JOUR LB - 172. AU - Penault-Llorca, F AU - Rudzinski, ER AU - Sepulveda, AR TI - Testing algorithm for identification of patients with TRK fusion cancer J2 - J Clin Pathol PY - 2019 VL - 72 SP - 460 EP - 467 UR - https://doi.org/10.1136/jclinpath-2018-205679 ER - TY - CHAP LB - 173. AU - Wright, C TI - Long Noncoding RNAs and Cancer A2 - Gray, S T2 - Epigenetic Cancer Therapy CY - London PB - Academic Press PY - 2015 SP - 91 EP - 114 UR - https://doi.org/10.1016/B978-0-12-800206-3.00005-7 ER - TY - JOUR LB - 174. AU - Marchiò, C AU - Scaltriti, M AU - Ladanyi, M AU - Iafrate, AJ AU - Bibeau, F AU - Dietel, M TI - ESMO recommendations on the standard methods to detectNTRKfusions in daily practice and clinical research J2 - Ann Oncol PY - 2019 VL - 30 SP - 1417 EP - 1427 UR - https://doi.org/10.1093/annonc/mdz204 ER - TY - JOUR LB - 175. AU - Sigal, DS AU - Bhangoo, MS AU - Hermel, JA AU - Pavlick, DC AU - Frampton, G AU - Miller, VA TI - Comprehensive genomic profiling identifies novelNTRKfusions in neuroendocrine tumors J2 - Oncotarget PY - 2018 VL - 9 SP - 35809 EP - 35812 UR - https://doi.org/10.18632/oncotarget.26260 ER - TY - JOUR LB - 176. AU - Okamura, R AU - Boichard, A AU - Kato, S AU - Sicklick, JK AU - Bazhenova, L AU - Kurzrock, R TI - Analysis ofNTRKalterations in pan-cancer adult and pediatric malignancies: implications forNTRK-targeted therapeutics J2 - JCO Precis Oncol PY - 2018 VL - 2018 UR - https://doi.org/10.1200/PO.18.00183 ER - TY - GEN LB - 177. AU - U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research TI - NDA Multidisciplinary Review and Evaluation NDA 210861 and NDA 211710 VITRAKVI (Larotrectinib) CY - Silver Spring, MD PB - FDA PY - 2016 ER - TY - JOUR LB - 178. AU - Amatu, A AU - Sartore-Bianchi, A AU - Siena, S TI - NTRKgene fusions as novel targets of cancer therapy across multiple tumour types J2 - ESMO Open PY - 2016 VL - 1 SP - e000023 UR - https://doi.org/10.1136/esmoopen-2015-000023 ER - TY - JOUR LB - 179. AU - Williams, HL AU - Walsh, K AU - Diamond, A AU - Oniscu, A AU - Deans, ZC TI - Validation of the Oncomine™ focus panel for next-generation sequencing of clinical tumour samples J2 - Virchows Arch PY - 2018 VL - 473 SP - 489 EP - 503 UR - https://doi.org/10.1007/s00428-018-2411-4 ER - TY - JOUR LB - 180. AU - Solomon, JP AU - Linkov, I AU - Rosado, A AU - Mullaney, K AU - Rosen, EY AU - Frosina, D TI - NTRKfusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls J2 - Mod Pathol PY - 2020 VL - 33 SP - 38 EP - 46 UR - https://doi.org/10.1038/s41379-019-0324-7 ER - TY - JOUR LB - 181. AU - Makretsov, N AU - He, M AU - Hayes, M AU - Chia, S AU - Horsman, DE AU - Sorensen, PH AU - Huntsman, DG TI - A fluorescence in situ hybridization study ofETV6–NTRK3fusion gene in secretory breast carcinoma J2 - Genes Chromosomes Cancer PY - 2004 VL - 40 SP - 152 EP - 157 UR - https://doi.org/10.1002/gcc.20028 ER - TY - GEN LB - 182. AU - Scottish Science Advisory Council (SSAC) TI - Informing the Future of Genomic Medicine in Scotland CY - Edinburgh PB - SSAC PY - 2019 ER - TY - RPRT LB - 183. AU - Canadian Agency for Drugs and Techonologies in Health (CADTH) TI - Larotrectinib (Vitrakvi) for Neurotrophic Tyrosine Receptor Kinase (NTRK) Positive Solid Tumours: Pan-Canadian Oncology Drug Review. Final Economic Guidance Report CY - Toronto, ON PB - CADTH PY - 2019 ER - TY - BOOK LB - 184. AU - Woods, B AU - Sideris, E AU - Palmer, S AU - Latimer, N AU - Soares, M TI - Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review CY - Sheffield PB - Decision Support Unit, ScHARR, University of Sheffield PY - 2017 ER - TY - BOOK LB - 185. AU - Latimer, NJ TI - NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations alongside Clinical Trials - Extrapolation with Patient-level Data CY - Sheffield PB - Decision Support Unit, ScHARR, University of Sheffield PY - 2011 ER - TY - JOUR LB - 186. AU - Ouwens, MJNM AU - Mukhopadhyay, P AU - Zhang, Y AU - Huang, M AU - Latimer, N AU - Briggs, A TI - Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations J2 - PharmacoEconomics PY - 2019 VL - 37 SP - 1129 EP - 1138 UR - https://doi.org/10.1007/s40273-019-00806-4 ER - TY - JOUR LB - 187. AU - Price, MJ AU - Welton, NJ AU - Briggs, AH AU - Ades, AE TI - Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information J2 - Value Health PY - 2011 VL - 14 SP - 205 EP - 218 UR - https://doi.org/10.1016/j.jval.2010.08.001 ER - TY - JOUR LB - 188. AU - Jackson, CH AU - Bojke, L AU - Thompson, SG AU - Claxton, K AU - Sharples, LD TI - A framework for addressing structural uncertainty in decision models J2 - Med Decis Making PY - 2011 VL - 31 SP - 662 EP - 674 UR - https://doi.org/10.1177/0272989X11406986 ER - TY - ELEC LB - 189. AU - Australian Government Department of Health TI - Co-dependent and Hybrid Technologies PY - 2017 UR - www1.health.gov.au/internet/hta/publishing.nsf/Content/co-1 M1 - 17 January 2020 ER - TY - JOUR LB - 190. AU - Soares, MO AU - Walker, S AU - Palmer, SJ AU - Sculpher, MJ TI - Establishing the value of diagnostic and prognostic tests in health technology assessment J2 - Med Decis Making PY - 2018 VL - 38 SP - 495 EP - 508 UR - https://doi.org/10.1177/0272989X17749829 ER - TY - JOUR LB - 191. AU - Albert, CM AU - Davis, JL AU - Federman, N AU - Casanova, M AU - Laetsch, TW TI - TRK fusion cancers in children: a clinical review and recommendations for screening J2 - J Clin Oncol PY - 2019 VL - 37 SP - 513 EP - 524 UR - https://doi.org/10.1200/JCO.18.00573 ER - TY - JOUR LB - 192. AU - Stinnett, AA AU - Mullahy, J TI - Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis J2 - Med Decis Making PY - 1998 VL - 18 IS - Suppl. 2 SP - 68 EP - 80 UR - https://doi.org/10.1177/0272989X98018002S09 ER - TY - BOOK LB - 193. AU - Briggs, A AU - Claxton, K AU - Sculpher, MJ TI - Decision Modelling for Health Economic Evaluation CY - Oxford PB - Oxford University Press PY - 2006 ER - TY - JOUR LB - 194. AU - Hettle, R AU - Corbett, M AU - Hinde, S AU - Hodgson, R AU - Jones-Diette, J AU - Woolacott, N AU - Palmer, S TI - The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal J2 - Health Technol Assess PY - 2017 VL - 21 IS - 7 UR - https://doi.org/10.3310/hta21070 ER - TY - RPRT LB - 195. AU - Grimm, S AU - Strong, M AU - Brennan, A AU - Wailoo, A TI - Framework for Analysing Risk in Health Technology Assessments and Its Application to Managed Entry Agreements. Report by the Decision Support Unit CY - Sheffield PB - Decision Support Unit, ScHARR, University of Sheffield PY - 2016 ER - TY - JOUR LB - 196. AU - Claxton, K TI - The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies J2 - J Health Econ PY - 1999 VL - 18 SP - 341 EP - 364 UR - https://doi.org/10.1016/S0167-6296(98)00039-3 ER - TY - JOUR LB - 197. AU - Claxton, K AU - Palmer, S AU - Longworth, L AU - Bojke, L AU - Griffin, S AU - Soares, M TI - A comprehensive algorithm for approval of health technologies with, without, or only in research: the key principles for informing coverage decisions J2 - Value Health PY - 2016 VL - 19 SP - 885 EP - 891 UR - https://doi.org/10.1016/j.jval.2016.03.2003 ER - TY - JOUR LB - 198. AU - Ades, AE AU - Lu, G AU - Claxton, K TI - Expected value of sample information calculations in medical decision modeling J2 - Med Decis Making PY - 2004 VL - 24 SP - 207 EP - 227 UR - https://doi.org/10.1177/0272989X04263162 ER - TY - GEN LB - 199. AU - NHS England Cancer Drugs Fund Team TI - Appraisal and Funding of Cancer Drugs from July 2016 (Including the New Cancer Drugs Fund): A New Deal for Patients, Taxpayers and Industry CY - London PB - NHS England PY - 2016 ER - TY - BOOK LB - 200. AU - Claxton, K TI - Pharmaceutical Pricing: Early Access, The Cancer Drugs Fund and the Role of NICE CY - York PB - Centre for Health Economics, University of York PY - 2016 ER - TY - JOUR LB - 201. AU - Grieve, R AU - Abrams, K AU - Claxton, K AU - Goldacre, B AU - James, N AU - Nicholl, J TI - Cancer Drugs Fund requires further reform J2 - BMJ PY - 2016 VL - 354 SP - i5090 UR - https://doi.org/10.1136/bmj.i5090 ER - TY - JOUR LB - 202. AU - Morrell, L AU - Wordsworth, S AU - Schuh, A AU - Middleton, MR AU - Rees, S AU - Barker, RW TI - Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals J2 - BMC Health Serv Res PY - 2018 VL - 18 SP - 393 UR - https://doi.org/10.1186/s12913-018-3162-2 ER - TY - JOUR LB - 203. AU - Strong, M AU - Oakley, JE AU - Brennan, A TI - Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach J2 - Med Decis Making PY - 2014 VL - 34 SP - 311 EP - 326 UR - https://doi.org/10.1177/0272989X13505910 ER - TY - JOUR LB - 204. AU - Strong, M AU - Oakley, JE AU - Brennan, A AU - Breeze, P TI - Estimating the expected value of sample information using the probabilistic sensitivity analysis sample: a fast, nonparametric regression-based method J2 - Med Decis Making PY - 2015 VL - 35 SP - 570 EP - 583 UR - https://doi.org/10.1177/0272989X15575286 ER - TY - JOUR LB - 205. AU - Willan, AR AU - Pinto, EM TI - The value of information and optimal clinical trial design J2 - Stat Med PY - 2005 VL - 24 SP - 1791 EP - 1806 UR - https://doi.org/10.1002/sim.2069 ER - TY - GEN LB - 206. AU - National Institute for Health and Care Excellence (NICE) TI - Guide to the Processes of Technology Appraisal CY - London PB - NICE PY - 2018 ER - TY - JOUR LB - 207. AU - Kim, DD AU - Basu, A TI - New metrics for economic evaluation in the presence of heterogeneity: focusing on evaluating policy alternatives rather than treatment alternatives J2 - Med Decis Making PY - 2017 VL - 37 SP - 930 EP - 941 UR - https://doi.org/10.1177/0272989X17702379 ER - TY - BOOK LB - 208. AU - Drummond, MF AU - Sculpher, MJ AU - Claxton, K AU - Stoddart, GL AU - Torrance, GW TI - Methods for the Economic Evaluation of Health Care Programmes CY - Oxford PB - Oxford University Press PY - 2015 ER - TY - JOUR LB - 209. AU - Claxton, K TI - OFT, VBP: QED? J2 - Health Econ PY - 2007 VL - 16 SP - 545 EP - 558 ER - TY - JOUR LB - 210. AU - Rothery, C AU - Claxton, K AU - Palmer, S AU - Epstein, D AU - Tarricone, R AU - Sculpher, M TI - Characterising uncertainty in the assessment of medical devices and determining future research needs J2 - Health Econ PY - 2017 VL - 26 IS - Suppl. 1 SP - 109 EP - 123 UR - https://doi.org/10.1002/hec.3467 ER - TY - JOUR LB - 211. AU - Kennedy-Martin, T AU - Curtis, S AU - Faries, D AU - Robinson, S AU - Johnston, J TI - A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results J2 - Trials PY - 2015 VL - 16 SP - 495 UR - https://doi.org/10.1186/s13063-015-1023-4 ER - TY - GEN LB - 212. AU - National Institute for Health and Care Excellence (NICE) TI - Pembrolizumab with Carboplatin and Paclitaxel for Untreated Metastatic Squamous Non-small-cell Lung Cancer IS - Technology Appraisal Guidance [TA600] CY - London PB - NICE PY - 2019 ER - TY - GEN LB - 213. AU - National Institute for Health and Care Excellence (NICE) TI - Pembrolizumab for Untreated PD-L1-positive Locally Advanced or Metastatic Urothelial Cancer when Cisplatin is Unsuitable IS - Technology Appraisal [TA674] CY - London PB - NICE PY - 2018 ER - TY - GEN LB - 214. AU - National Institute for Health and Care Excellence (NICE) TI - Pembrolizumab for Untreated Metastatic or Unresectable Recurrent Squamous Cell Head and Neck Cancer IS - Technology Appraisal Guidance [TA661] CY - London PB - NICE PY - 2020 UR - www.nice.org.uk/guidance/TA661 Y2 - 20 February 2020 ER - TY - ELEC LB - 215. AU - European Medicines Agency TI - Workshop on Site and Histology – Independent Indications of Oncology PY - 2018 UR - www.ema.europa.eu/en/events/workshop-site-histology-independent-indications-oncology M1 - October 2021 ER - TY - ELEC LB - 216. AU - European Medicines Agency TI - Workshop on Single-arm Studies in Oncology PY - 2016 UR - www.ema.europa.eu/en/events/workshop-single-arm-trials-oncology M1 - October 2021 ER - TY - ELEC LB - 217. AU - US Food and Drug Administration TI - Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease PY - 2018 UR - www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM588884.pdf M1 - October 2021 ER - TY - ELEC LB - 218. AU - US Food and Drug Administration TI - Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics PY - 2018 UR - www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM621817.pdf M1 - October 2021 ER - TY - ELEC LB - 219. AU - US Department of Health and Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research TI - Guidance for Industry: Expedited Programs for Serious Conditions – Drugs and Biologics PY - 2014 UR - www.fda.gov/downloads/Drugs/Guidances/UCM358301.pdf M1 - October 2021 ER - TY - ELEC LB - 220. AU - Food and Drug Administration TI - Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure UR - www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure M1 - 17 January 2020 ER - TY - ELEC LB - 221. AU - Food and Drug Administration (FDA) TI - Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry PY - 2018 UR - www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-trial-endpoints-approval-cancer-drugs-and-biologics M1 - 17 January 2020 ER - TY - ELEC LB - 222. AU - US Food and Drug Administration TI - Tissue Agnostic Therapies in Oncology: Regulatory Considerations for Orphan Drug Designation UR - www.fda.gov/downloads/NewsEvents/MeetingsConferencesWorkshops/UCM598186.pdf M1 - October 2021 ER - TY - ELEC LB - 223. AU - European Medicines Agency TI - Essential Considerations for Successful Qualification of Novel Methodologies PY - 2017 UR - www.ema.europa.eu/documents/other/essential-considerations-successful-qualification-novel-methodologies_en.pdf M1 - October 2021 ER - TY - ELEC LB - 224. AU - European Medicines Agency TI - Biostatistics PY - 2021 UR - www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/clinical-efficacy-safety/biostatistics M1 - October 2021 ER - TY - ELEC LB - 225. AU - European Medicines Agency TI - Predictive Biomarker-based Assay Development in the Context of Drug Development and Lifecycle PY - 2017 UR - www.ema.europa.eu/en/predictive-biomarker-based-assay-development-context-drug-development-lifecycle M1 - October 2021 ER - TY - ELEC LB - 226. AU - European Medicines Agency TI - Guideline on the Evaluation of Anticancer Medicinal Products in Man Rev. 5 PY - 2017 UR - www.ema.europa.eu/documents/scientific-guideline/guideline-evaluation-anticancer-medicinal-products-man-revision-5_en.pdf M1 - October 2021 ER - TY - ELEC LB - 227. AU - European Medicines Agency TI - Appendix 4 to the Guideline on the Evaluation of Anticancer Medicinal Products in Man PY - 2015 UR - www.ema.europa.eu/documents/scientific-guideline/evaluation-anticancer-medicinal-products-man-appendix-4-condition-specific-guidance-rev2_en.pdf M1 - October 2021 ER - TY - GEN LB - 228. AU - National Institute for Health and Care Excellence (NICE) TI - Ceritinib for Previously Treated Anaplastic Lymphoma Kinase Positive Non-Small-Cell Lung Cancer. Technology Appraisal Guidance [TA395] CY - London PB - NICE PY - 2016 ER - TY - JOUR LB - 229. AU - Kim, DW AU - Mehra, R AU - Tan, DS AU - Felip, E AU - Chow, LQ AU - Camidge, DR AU - Vansteenkiste, J TI - Activity and safety in ceritinib in patients withALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial J2 - Lancet Oncol PY - 2016 VL - 17 SP - 452 EP - 463 UR - https://doi.org/10.1016/S1470-2045(15)00614-2 ER - TY - JOUR LB - 230. AU - Crinò, L AU - Ahn, MJ AU - De Marinis, F AU - Groen, HJ AU - Wakelee, H AU - Hida, T TI - Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients withALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2 J2 - J Clin Oncol PY - 2016 VL - 34 SP - 2866 EP - 2878 UR - https://doi.org/10.1200/JCO.2015.65.5936 ER - TY - GEN LB - 231. AU - National Institute for Health and Care Excellence (NICE) TI - Osimertinib for Treating Locally Advanced or MetastaticEGFRT790M Mutation-positive Non-small-cell Lung Cancer IS - Technology Appraisal Guidance [TA416] CY - London PB - NICE PY - 2016 ER - TY - JOUR LB - 232. AU - Yang, JC AU - Ahn, MJ AU - Kim, DW AU - Ramalingam, SS AU - Sequist, LV AU - Su, WC TI - Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component J2 - J Clin Oncol PY - 2017 VL - 35 SP - 1288 EP - 1296 UR - https://doi.org/10.1200/JCO.2016.70.3223 ER - TY - JOUR LB - 233. AU - Goss, G AU - Tsai, CM AU - Shepherd, FA AU - Bazhenova, L AU - Lee, JS AU - Chang, GC TI - Osimertinib for pretreatedEGFRThr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study J2 - Lancet Oncol PY - 2016 VL - 17 SP - 1643 EP - 1652 UR - https://doi.org/10.1016/S1470-2045(16)30508-3 ER - TY - JOUR LB - 234. AU - Ahn, MJ AU - Tsai, CM AU - Shepherd, FA AU - Bazhenova, L AU - Sequist, LV AU - Hida, T TI - Osimertinib in patients with T790M mutation-positive, advanced non–small cell lung cancer: long-term follow-up from a pooled analysis of 2 phase 2 studies J2 - Cancer PY - 2019 VL - 125 SP - 892 EP - 901 UR - https://doi.org/10.1002/cncr.31891 ER - TY - GEN LB - 235. AU - National Institute for Health and Care Excellence (NICE) TI - Nivolumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma IS - Technology Appraisal Guidance [TA462] CY - London PB - NICE PY - 2017 ER - TY - JOUR LB - 236. AU - Younes, A AU - Santoro, A AU - Shipp, M AU - Zinzani, PL AU - Timmerman, JM AU - Ansell, S TI - Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial J2 - Lancet Oncol PY - 2016 VL - 17 SP - 1283 EP - 1294 UR - https://doi.org/10.1016/S1470-2045(16)30167-X ER - TY - JOUR LB - 237. AU - Lesokhin, AM AU - Ansell, SM AU - Arman, P AU - Scott, EC AU - Halwani, A AU - Gutierrez, M TI - Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase 1b study J2 - J Clin Oncol PY - 2016 VL - 34 SP - 2698 EP - 2704 UR - https://doi.org/10.1200/JCO.2015.65.9789 ER - TY - GEN LB - 238. AU - National Institute for Health and Care Excellence (NICE) TI - Venetoclax for Treating Chronic Lymphocytic Leukaemia IS - Technology Appraisal Guidance [TA487] CY - London PB - NICE PY - 2017 ER - TY - JOUR LB - 239. AU - Davids, MS AU - Roberts, AW AU - Seymour, JK AU - Pagel, JM AU - Kahl, BS AU - Wierda, WG TI - Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma J2 - J Clin Oncol PY - 2017 VL - 35 SP - 826 EP - 833 UR - https://doi.org/10.1200/JCO.2016.70.4320 ER - TY - JOUR LB - 240. AU - Stilgenbauer, S AU - Eichhorst, B AU - Schetelig, J AU - Coutre, S AU - Seymour, JF AU - Munir, T TI - Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study J2 - Lancet Oncol PY - 2016 VL - 17 SP - 768 EP - 778 UR - https://doi.org/10.1016/S1470-2045(16)30019-5 ER - TY - JOUR LB - 241. AU - Stilgenbauer, S AU - Eichhorst, B AU - Schetelig, J AU - Hillmen, P AU - Seymour, JF AU - Coutre, S TI - Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial J2 - J Clin Oncol PY - 2018 VL - 36 SP - 1973 EP - 1980 UR - https://doi.org/10.1200/JCO.2017.76.6840 ER - TY - JOUR LB - 242. AU - Coutre, S AU - Choi, M AU - Furman, RR AU - Eradat, H AU - Heffner, L AU - Jones, JA TI - Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy J2 - Blood PY - 2018 VL - 131 SP - 1704 EP - 1711 UR - https://doi.org/10.1182/blood-2017-06-788133 ER - TY - JOUR LB - 243. AU - Jones, JA AU - Mato, AR AU - Wierda, WG AU - Davids, MS AU - Choi, M AU - Cheson, BD TI - Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial J2 - Lancet Oncol PY - 2018 VL - 19 SP - 65 EP - 75 UR - https://doi.org/10.1016/S1470-2045(17)30909-9 ER - TY - GEN LB - 244. AU - National Institute for Health and Care Excellence (NICE) TI - Atezolizumab for Untreated PD-L1-Positive Locally Advanced or Metastatic Urothelial Cancer When Cisplatin is Unsuitable IS - Technology Appraisal Guidance [TA492] CY - London PB - NICE PY - 2018 ER - TY - JOUR LB - 245. AU - Balar, AV AU - Galsky, MD AU - Rosenberg, JE AU - Powles, T AU - Petrylak, DP AU - Bellmunt, J TI - Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial J2 - Lancet Oncol PY - 2017 VL - 389 SP - 67 EP - 76 UR - https://doi.org/10.1016/S0140-6736(16)32455-2 ER - TY - JOUR LB - 246. AU - Necchi, A AU - Joseph, RW AU - Loriot, Y AU - Hoffman-Censits, J AU - Perez-Gracia, JL AU - Petrylak, DP TI - Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study J2 - Ann Oncol PY - 2017 VL - 28 SP - 3044 EP - 3050 UR - https://doi.org/10.1093/annonc/mdx518 ER - TY - JOUR LB - 247. AU - Rosenberg, JE AU - Hoffman-Censits, J AU - Powles, T AU - van der Heijden, MS AU - Balar, AV AU - Necchi, A TI - Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial J2 - Lancet PY - 2016 VL - 387 SP - 1909 EP - 1920 UR - https://doi.org/10.1016/S0140-6736(16)00561-4 ER - TY - GEN LB - 248. AU - National Institute for Health and Care Excellence (NICE) TI - Daratumumab Monotherapy for Treating Relapsed and Refractory Multiple Myeloma IS - Technology Appraisal Guidance [TA510] CY - London PB - NICE PY - 2018 ER - TY - JOUR LB - 249. AU - Lonial, S AU - Weiss, BM AU - Usmani, SZ AU - Singhai, S AU - Chari, A AU - Bahlis, NJ TI - Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial J2 - Lancet PY - 2016 VL - 387 SP - 1551 EP - 1560 UR - https://doi.org/10.1016/S0140-6736(15)01120-4 ER - TY - JOUR LB - 250. AU - Lokhorst, HM AU - Plesner, T AU - Laubach, JP AU - Nahi, H AU - Gimsing, P AU - Hansson, M TI - Targeting CD38 with daratumumab monotherapy in multiple myeloma J2 - New Engl J Med PY - 2015 VL - 373 SP - 1207 EP - 1219 UR - https://doi.org/10.1056/NEJMoa1506348 ER - TY - JOUR LB - 251. AU - Usmani, SZ AU - Weiss, BM AU - Plesner, T AU - Bahlis, NJ AU - Belch, A AU - Lonial, S TI - Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma J2 - Blood PY - 2016 VL - 128 SP - 37 EP - 44 UR - https://doi.org/10.1182/blood-2016-03-705210 ER - TY - GEN LB - 252. AU - National Institute for Health and Care Excellence (NICE) TI - Avelumab for Treating Metastatic Merkel Cell Carcinoma IS - Technology Appraisal Guidance [TA517] CY - London PB - NICE PY - 2017 ER - TY - JOUR LB - 253. AU - Kaufman, HL AU - Russell, J AU - Hamid, O AU - Bhatia, S AU - Terheyden, P AU - D’Angelo, SP TI - Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial J2 - Lancet Oncol PY - 2016 VL - 17 SP - 1374 EP - 1385 UR - https://doi.org/10.1016/S1470-2045(16)30364-3 ER - TY - JOUR LB - 254. AU - D’Angelo, SP AU - Russell, J AU - Lebbé, C AU - Chmielowski, B AU - Gambichler, T AU - Grob, JJ TI - Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial J2 - JAMA Oncol PY - 2018 VL - 4 SP - e180077 UR - https://doi.org/10.1001/jamaoncol.2018.0077 ER - TY - GEN LB - 255. AU - National Institute for Health and Care Excellence (NICE) TI - Crizotinib for TreatingROS1-positive Advanced Non-small-cell Lung Cancer IS - Technology Appraisal Guidance [TA529] CY - London PB - NICE PY - 2018 ER - TY - JOUR LB - 256. AU - Shaw, AT AU - Ou, SHI AU - Bang, YJ AU - Camidge, DR AU - Solomon, BJ AU - Salgia, R TI - Crizotinib inROS1-rearranged non–small-cell lung cancer J2 - New Engl J Med PY - 2014 VL - 371 SP - 1963 EP - 1971 UR - https://doi.org/10.1056/NEJMoa1406766 ER - TY - JOUR LB - 257. AU - Shaw, AT AU - Riely, GJ AU - Bang, YJ AU - Kim, DW AU - Camidge, DR AU - Solomon, BJ TI - Crizotinib inROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001 J2 - Ann Oncol PY - 2019 VL - 30 SP - 1121 EP - 1126 UR - https://doi.org/10.1093/annonc/mdz131 ER - TY - GEN LB - 258. AU - National Institute for Health and Care Excellence (NICE) TI - Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma IS - Technology Appraisal Guidance [TA540] CY - London PB - NICE PY - 2018 ER - TY - JOUR LB - 259. AU - Chen, R AU - Zinzani, PL AU - Fanale, MA AU - Armand, P AU - Johnson, NA AU - Brice, P TI - Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma J2 - J Clin Oncol PY - 2017 VL - 35 SP - 2125 EP - 2132 UR - https://doi.org/10.1200/JCO.2016.72.1316 ER - TY - GEN LB - 260. AU - National Institute for Health and Care Excellence (NICE) TI - Brigatinib for TreatingALK-positive Non-small-cell Lung Cancer after Crizotinib IS - Technology Appraisal Guidance [TA571] CY - London PB - NICE PY - 2019 ER - TY - JOUR LB - 261. AU - Kim, DW AU - Tiseo, M AU - Ahn, MJ AU - Reckamp, KL AU - Hansen, KH AU - Kim, SW TI - Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial J2 - J Clin Oncol PY - 2017 VL - 35 SP - 2490 EP - 2498 UR - https://doi.org/10.1200/JCO.2016.71.5904 ER - TY - JOUR LB - 262. AU - Gettinger, SN AU - Bazhenova, LA AU - Langer, CJ AU - Salgia, R AU - Gold, KA AU - Rosell, R TI - Activity and safety of brigatinib inALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial J2 - Lancet Oncol PY - 2016 VL - 17 SP - 1683 EP - 1696 UR - https://doi.org/10.1016/S1470-2045(16)30392-8 ER - TY - JOUR LB - 263. AU - Hatswell, AJ AU - Freemantle, N AU - Baio, G TI - Economic evaluations of pharmaceuticals granted a marketing authorisation without the results of randomised trials: a systematic review and taxonomy J2 - PharmacoEconomics PY - 2017 VL - 35 SP - 163 EP - 176 UR - https://doi.org/10.1007/s40273-016-0460-6 ER - TY - RPRT LB - 264. AU - Faria, R AU - Hernandez Alava, M AU - Manca, A AU - Wailoo, AJ TI - The Use of Observational Data to Inform Estimates of Treatment Effectiveness for Technology Appraisal: Methods for Comparative Individual Patient Data. Report by the Decision Support Unit CY - Sheffield PB - Decision Support Unit, ScHARR, University of Sheffield PY - 2015 ER - TY - RPRT LB - 265. AU - Bell, H AU - Wailoo, A AU - Hernandez, M AU - Grieve, R AU - Faria, R AU - Gibson, L TI - The Use of Real World Data for the Estimation of Treatment Effects in NICE Decision Making. Report by the Decision Support Unit CY - Sheffield PB - Decision Support Unit, ScHARR, University of Sheffield PY - 2016 ER - TY - JOUR LB - 266. AU - Wright, SJ AU - Newman, WG AU - Payne, K TI - Accounting for capacity constraints in economic evaluations of precision medicine: a systematic review J2 - PharmacoEconomics PY - 2019 VL - 37 SP - 1011 EP - 1027 UR - https://doi.org/10.1007/s40273-019-00801-9 ER - TY - JOUR LB - 267. AU - Marmor, S AU - Portschy, PR AU - Tuttle, TM AU - Virnig, BA TI - The rise in appendiceal cancer incidence: 2000–2009 J2 - J Gastrointest Surg PY - 2015 VL - 19 SP - 743 EP - 750 UR - https://doi.org/10.1007/s11605-014-2726-7 ER - TY - ELEC LB - 268. AU - World Population Review TI - Western European Countries 2020 PY - 2019 UR - http://worldpopulationreview.com/countries/western-european-countries/ M1 - 12 December 2019 ER - TY - ELEC LB - 269. AU - Office for National Statistics TI - Cancer Registration Statistics, England: 2017 PY - 2019 UR - www.ons.gov.uk/releases/cancerregistrationstatisticsengland2017 M1 - June 2019 ER - TY - BOOK LB - 270. AU - Cancer Research, UK TI - Breast Cancer Incidence by Stage at Diagnosis CY - London PB - Cancer Research UK PY - 2014 UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/incidence Y2 - June 2019 ER - TY - BOOK LB - 271. AU - Coombes, N AU - Elliss-Brookes, L AU - Johnson, S AU - Lyons, J AU - Mackay, C AU - Morement, H TI - National Cancer Intelligence Network. Rare and Less Common Cancers: Incidence and Mortality in England, 2010 to 2013 CY - London PB - Public Health England PY - 2015 ER - TY - JOUR LB - 272. AU - Tsuchiya, N AU - Sawada, Y AU - Endo, I AU - Saito, K AU - Uemura, Y AU - Nakatsura, T TI - Biomarkers for the early diagnosis of hepatocellular carcinoma J2 - World J Gastroenterol PY - 2015 VL - 21 SP - 10573 EP - 10583 UR - https://doi.org/10.3748/wjg.v21.i37.10573 ER - TY - JOUR LB - 273. AU - Thrumurthy, SG AU - Thrumurthy, SS AU - Gilbert, CE AU - Ross, P AU - Haji, A TI - Colorectal adenocarcinoma: risks, prevention and diagnosis J2 - BMJ PY - 2016 VL - 354 SP - i3590 UR - https://doi.org/10.1136/bmj.i3590 ER - TY - BOOK LB - 274. AU - Cancer Research, UK TI - Bowel Cancer Incidence by Stage at Diagnosis CY - London PB - Cancer Research UK PY - 2016 UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/bowel-cancer Y2 - June 2019 ER - TY - JOUR LB - 275. AU - Starczewska Amelio, JM AU - Cid Ruzafa, J AU - Desai, K AU - Tzivelekis, S AU - Muston, D AU - Khalid, JM TI - Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model J2 - BMC Cancer PY - 2014 VL - 14 SP - 364 UR - https://doi.org/10.1186/1471-2407-14-364 ER - TY - ELEC LB - 276. AU - PDQ Adult Treatment Editorial Board TI - Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®): Patient Version PY - 2020 UR - https://www.ncbi.nlm.nih.gov/books/NBK65929/ M1 - November 2021 ER - TY - JOUR LB - 277. AU - Orbach, D AU - Rey, A AU - Cecchetto, G AU - Oberlin, O AU - Casanova, M AU - Thebaud, E TI - Infantile fibrosarcoma: management based on the European experience J2 - J Clin Oncol PY - 2010 VL - 28 SP - 318 EP - 323 UR - https://doi.org/10.1200/JCO.2009.21.9972 ER - TY - JOUR LB - 278. AU - Skálová, A AU - Vanecek, T AU - Sima, R AU - Laco, J AU - Weinreb, I AU - Perez-Ordonez, B TI - Mammary analogue secretory carcinoma of salivary glands, containing theETV6–NTRK3fusion gene: a hitherto undescribed salivary gland tumor entity J2 - Am J Surg Pathol PY - 2010 VL - 34 SP - 599 EP - 608 UR - https://doi.org/10.1097/PAS.0b013e3181d9efcc ER - TY - JOUR LB - 279. AU - Luk, PP AU - Selinger, CI AU - Eviston, TJ AU - Lum, T AU - Yu, B AU - O’Toole, SA TI - Mammary analogue secretory carcinoma: an evaluation of its clinicopathological and genetic characteristics J2 - Pathology PY - 2015 VL - 47 SP - 659 EP - 666 UR - https://doi.org/10.1097/PAT.0000000000000322 ER - TY - JOUR LB - 280. AU - Sethi, R AU - Kozin, E AU - Remenschneider, A AU - Meier, J AU - VanderLaan, P AU - Faquin, W TI - Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy J2 - Laryngoscope PY - 2014 VL - 124 SP - 188 EP - 195 UR - https://doi.org/10.1002/lary.24254 ER - TY - BOOK LB - 281. AU - Cancer Research, UK TI - Melanoma Skin Cancer Incidence by Stage at Diagnosis CY - London PB - Cancer Research UK PY - 2016 UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/melanoma-skin-cancer/incidence Y2 - June 2019 ER - TY - RPRT LB - 282. AU - Care Quality Improvement Department, Royal College of Physicians TI - National Lung Cancer Audit Annual Report 2018 (for the Audit Period 2017) CY - London PB - Healthcare Quality Improvement Partnership (HQIP) PY - 2019 ER - TY - BOOK LB - 283. AU - Pancreatic Cancer, UK TI - Types of Pancreatic Cancer CY - London PB - Pancreatic Cancer UK PY - 2018 UR - www.pancreaticcancer.org.uk/information-and-support/facts-about-pancreatic-cancer/types-of-pancreatic-cancer/ Y2 - 16 December 2019 ER - TY - BOOK LB - 284. AU - Cancer Research, UK TI - Pancreatic Cancer Incidence by Stage at Diagnosis CY - London PB - Cancer Research UK PY - 2016 UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/pancreatic-cancer/incidence#heading-Three Y2 - June 2019 ER - TY - ELEC LB - 285. AU - Cancer Research, UK TI - Soft Tissue Sarcoma Incidence Statistics PY - 2010 UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/soft-tissue-sarcoma/incidence#heading-Four M1 - 27 February 2019 ER - TY - ELEC LB - 286. AU - American Cancer Society TI - Cancer Facts and Figures PY - 2017 UR - www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html M1 - 24 January 2020 ER - TY - JOUR LB - 287. AU - Deen, MH AU - Burke, KM AU - Janitz, A AU - Campbell, J TI - Cancers of the thyroid: overview and statistics in the United States and Oklahoma J2 - J Okla State Med Assoc PY - 2016 VL - 109 SP - 333 EP - 338 ER - TY - BOOK LB - 288. AU - Cancer Research, UK TI - Cervical Cancer Incidence by Stage at Diagnosis CY - London PB - Cancer Research UK PY - 2016 UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/cervical-cancer/incidence#heading-Three Y2 - June 2019 ER - TY - JOUR LB - 289. AU - Gooskens, SL AU - Houwing, ME AU - Vujanic, GM AU - Dome, JS AU - Diertens, T AU - Coulomb-l’Herminé, A TI - Congenital mesoblastic nephroma 50 years after its recognition: a narrative review J2 - Pediatr Blood Cancer PY - 2017 VL - 64 SP - e26437 UR - https://doi.org/10.1002/pbc.26437 ER - TY - GEN LB - 290. AU - National Institute for Health and Care Excellence (NICE) TI - Pembrolizumab for Previously Treated Oesophageal or Gastrooesophageal Junction Cancer Draft Scope CY - London PB - NICE PY - 2018 ER - TY - BOOK LB - 291. AU - Cancer Research, UK TI - Oesophageal Cancer Incidence by Stage at Diagnosis CY - London PB - Cancer Research UK PY - 2016 UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/oesophageal-cancer/incidence Y2 - June 2019 ER - TY - ELEC LB - 292. AU - Cancer Research, UK TI - Head and Neck Cancers Statistics PY - 2016 UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/head-and-neck-cancers M1 - June 2019 ER - TY - GEN LB - 293. AU - Public Health England TI - Glioblastoma in England 2007-2011 CY - London PB - Public Health England PY - 2016 ER - TY - JOUR LB - 294. AU - Wang, Y AU - Jiang, T TI - Understanding high grade glioma: molecular mechanism, therapy and comprehensive management J2 - Cancer Lett PY - 2013 VL - 331 SP - 139 EP - 146 UR - https://doi.org/10.1016/j.canlet.2012.12.024 ER - TY - GEN LB - 295. AU - UK and Ireland Neuroendcrine Tumour Society (UKI NETS) TI - Incidence and Prevalence of Neuroendocrine Tumours in England CY - London PB - Endocrine Abstracts PY - 2017 ER - TY - GEN LB - 296. AU - Cancer Research UK TI - Ovarian Cancer Incidence by Stage at Diagnosis CY - London PB - Cancer Research UK PY - 2016 UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer/incidence Y2 - June 2019 ER - TY - BOOK LB - 297. AU - Farrimond, J TI - Analysis of the Cancer Registry Combined Database for Use with the Brain and CNS Registry CY - London PB - National Cancer Intelligence Network, Eastern Cancer Registration and Information Centre PY - 2010 ER - TY - BOOK LB - 298. AU - Cancer Research, UK TI - Children’s Cancer Incidence Statistics CY - London PB - Cancer Research UK PY - 2014 UR - www.cancerresearchuk.org/health-professional/cancer-statistics/childrens-cancers Y2 - June 2019 ER - TY - JOUR LB - 299. AU - Austin, MT AU - Xing, Y AU - Hayes-Jordan, AA AU - Lally, KP AU - Cormier, JN TI - Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States J2 - J Pediatr Surg PY - 2013 VL - 48 SP - 2207 EP - 2213 UR - https://doi.org/10.1016/j.jpedsurg.2013.06.002 ER - TY - JOUR LB - 300. AU - Brzeziańska, E AU - Karbownik, M AU - Migdalska-Sek, M AU - Pastuszak-Lewandoska, D AU - Włoch, J AU - Lewiński, A TI - Molecular analysis of theRETandNTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population J2 - Mutat Res PY - 2006 VL - 599 SP - 26 EP - 35 UR - https://doi.org/10.1016/j.mrfmmm.2005.12.013 ER - TY - GEN LB - 301. AU - Cancer Research UK TI - Prostate Cancer Incidence by Stage at Diagnosis CY - London PB - Cancer Research UK PY - 2016 UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/prostate-cancer/incidence#heading-Three Y2 - June 2019 ER - TY - BOOK LB - 302. AU - Cancer Research, UK TI - Kidney Cancer: Stages, Types and Grades CY - London PB - Cancer Research UK PY - 2016 UR - www.cancerresearchuk.org/about-cancer/kidney-cancer/stages-types-grades/types-grades Y2 - December 2019 ER - TY - JOUR LB - 303. AU - Horowitz, DP AU - Sharma, CS AU - Connolly, E AU - Gidea-Addeo, D AU - Deutsch, I TI - Secretory carcinoma of the breast: results from the survival, epidemiology and end results database J2 - Breast PY - 2012 VL - 21 SP - 350 EP - 353 UR - https://doi.org/10.1016/j.breast.2012.02.013 ER - TY - JOUR LB - 304. AU - Jacob, JD AU - Hodge, C AU - Franko, J AU - Pezzi, CM AU - Goldman, CD AU - Klimberg, VS TI - Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base J2 - J Surg Oncol PY - 2016 VL - 113 SP - 721 EP - 725 UR - https://doi.org/10.1002/jso.24241 ER - TY - BOOK LB - 305. AU - Rushton, L AU - Bagga, S AU - Bevan, R AU - Brown, T AU - Cherrie, J AU - Holmes, P TI - The Burden of Occupational Cancer in Great Britain CY - London PB - Health & Safety Executive PY - 2010 ER - TY - ELEC LB - 306. AU - Cancer Research UK TI - Uterine Cancer Incidence By Stage At Diagnosis PY - 2016 UR - www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/uterine-cancer/incidence#heading-Three M1 - June 2019 ER - TY - JOUR LB - 307. AU - Lee, SJ AU - Kim, NKD AU - Lee, S-H AU - Kim, ST AU - Park, SH AU - Park, JO TI - NTRKgene amplification in patients with metastatic cancer J2 - Precision Future Med PY - 2017 VL - 1 SP - 129 EP - 137 UR - https://doi.org/10.23838/pfm.2017.00142 ER - TY - JOUR LB - 308. AU - Lange, AM AU - Lo, HW TI - Inhibiting TRK proteins in clinical cancer therapy J2 - Cancers PY - 2018 VL - 10 SP - E105 ER - TY - GEN LB - 309. AU - National Cancer Institute TI - Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ®)–Health Professional Version CY - Rockville, MD PB - National Cancer Institute PY - 2018 UR - www.cancer.gov/types/soft-tissue-sarcoma/hp/gist-treatment-pdq Y2 - June 2019 ER - TY - JOUR LB - 310. AU - Demetri, GD AU - Paz-Ares, L AU - Farago, AF AU - Liu, SV AU - Chawla, SP AU - Tosi, D TI - Efficacy and safety of entrectinib in patients withNTRKfusion-positive tumours: pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001 J2 - Ann Oncol PY - 2018 VL - 29 SP - ix175 UR - https://doi.org/10.1093/annonc/mdy483.003 ER - TY - JOUR LB - 311. AU - Hyman, D AU - van Tilburg, C AU - Albert, C AU - Tan, D AU - Geoerger, B AU - Farago, A TI - 445PD Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer J2 - Ann Oncol PY - 2019 VL - 30 SP - v162 EP - v163 UR - https://doi.org/10.1093/annonc/mdz244.007 ER - TY - BOOK LB - 312. AU - Georghiou, T AU - Bardsley, M TI - Exploring the Cost of End of Life Care CY - London PB - Nuffield Trust PY - 2014 ER -